FAQ

DMP 696

Known as: 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)(1,5-a)pyrazolo-1,3,5-triazine, DMP-696, DMP696 
 

Topic mentions per year

Topic mentions per year

2000-2012
012320002012

Related topics

Related topics

2 relations

Broader (2)

PyrazolesTriazines

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
DMP 696
Triazines
Pyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Consolidation of Remote Fear Memories Involves Corticotropin-Releasing Hormone (CRH) Receptor Type 1-Mediated Enhancement of AMPA Receptor GluR1 Signaling in the Dentate Gyrus
Persistent dreadful memories and hyperarousal constitute prominent psychopathological features of posttraumatic stress disorder… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence.
Chronic stress is widely regarded as a key risk factor for a variety of diseases. A large number of paradigms have been used to… (More)
Is this relevant?
2007
2007
Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear.
The basolateral amygdala complex (BLA) and central amygdala nucleus (CeA) are involved in fear and anxiety. In addition, the BLA… (More)
Is this relevant?
2006
2006
Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists.
Chronic administration of antidepressants is required for their efficacy, suggesting the involvement of long-term modifications… (More)
Is this relevant?
2004
2004
Differential regulation of behavioral, genomic, and neuroendocrine responses by CRF infusions in rats.
Studies suggest that behavioral, genomic, and endocrine functions mediated by central corticotropin-releasing factor (CRF… (More)
Is this relevant?
2004
2004
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
The development of selective corticotropin-releasing factor type-1 (CRF1) receptor antagonists represents a potential novel… (More)
Is this relevant?
2003
2003
Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
4-(1,3-Dimethoxyprop-2-ylamine)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine (DMP696) is a highly selective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2002
2002
Effects of a Non-peptide CRF Antagonist (DMP696) on the Behavioral and Endocrine Sequelae of Maternal Separation
We examined whether blockade of corticotropin-releasing factor (CRF) receptors by a non-peptide CRF antagonist (DMP696) would… (More)
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2002
2002
The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats
Abstract Rationale. CRF1 antagonists may be effective in the treatment of anxiety disorders while having fewer side effects… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
Structure-activity studies in the pyrazolo[1,5-a]-1,3,5-triazine series led to the discovery that compound 11i (DMP696) is a… (More)
Is this relevant?